PDB Short entry for 2CCH HEADER CELL CYCLE 16-JAN-06 2CCH TITLE THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE TITLE 2 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.-; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: PHOSPHORYLATED ON THR160; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN A2; COMPND 10 CHAIN: B, D; COMPND 11 FRAGMENT: CYCLIN FOLD FRAGMENT RESIDUES 175-432; COMPND 12 SYNONYM: CYCLIN-A; COMPND 13 ENGINEERED: YES; COMPND 14 MOL_ID: 3; COMPND 15 MOLECULE: CELL DIVISION CONTROL PROTEIN 6 HOMOLOG; COMPND 16 CHAIN: E, F; COMPND 17 FRAGMENT: PEPTIDE DERIVED FROM SUBSTRATE/RECRUITMENT REGION OF CDC6 COMPND 18 RESIDUE 89-100; COMPND 19 SYNONYM: CDC6-BIS, CDC6-RELATED PROTEIN, P62, CDC6, HSCDC6, HSCDC18; COMPND 20 ENGINEERED: YES; COMPND 21 OTHER_DETAILS: GAMMA PHOSPHATE OF ATP IS COVALENTLY ATTACHED BY A COMPND 22 LINKER TO THE AMINO ANALOGUE OF THE OH ACCEPTOR AMINO ACID LOCATED IN COMPND 23 THE CDC6 SUBSTRATE PEPTIDE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 13 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 14 EXPRESSION_SYSTEM_PLASMID: PGEX; SOURCE 15 MOL_ID: 3; SOURCE 16 SYNTHETIC: YES; SOURCE 17 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 18 ORGANISM_TAXID: 9606 KEYWDS COMPLEX(TRANSFERASE-CELL DIVISION), ATP-BINDING, CDK2, CELL CYCLE, KEYWDS 2 CELL DIVISION, CYCLIN, MITOSIS, NUCLEAR PROTEIN, PEPTIDE KEYWDS 3 SPECIFICITY, PHOSPHORYLATION, POLYMORPHISM, PROTEIN KINASE, KEYWDS 4 RECRUITMENT, SERINE-THREONINE-PROTEIN KINASE, SERINE/THREONINE- KEYWDS 5 PROTEIN KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR K.Y.CHENG,M.E.M.NOBLE,V.SKAMNAKI,N.R.BROWN,E.D.LOWE,L.KONTOGIANNIS, AUTHOR 2 K.SHEN,P.A.COLE,G.SILIGARDI,L.N.JOHNSON REVDAT 5 13-DEC-23 2CCH 1 REMARK REVDAT 4 27-FEB-19 2CCH 1 REMARK LINK REVDAT 3 24-FEB-09 2CCH 1 VERSN REVDAT 2 09-AUG-06 2CCH 1 JRNL REVDAT 1 03-MAY-06 2CCH 0 JRNL AUTH K.Y.CHENG,M.E.M.NOBLE,V.SKAMNAKI,N.R.BROWN,E.D.LOWE, JRNL AUTH 2 L.KONTOGIANNIS,K.SHEN,P.A.COLE,G.SILIGARDI,L.N.JOHNSON JRNL TITL THE ROLE OF THE PHOSPHO-CDK2/CYCLIN A RECRUITMENT SITE IN JRNL TITL 2 SUBSTRATE RECOGNITION JRNL REF J.BIOL.CHEM. V. 281 23167 2006 JRNL REFN ISSN 0021-9258 JRNL PMID 16707497 JRNL DOI 10.1074/JBC.M600480200 REMARK 2 REMARK 2 RESOLUTION. 1.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 96.67 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 3 NUMBER OF REFLECTIONS : 159215 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.150 REMARK 3 R VALUE (WORKING SET) : 0.148 REMARK 3 FREE R VALUE : 0.182 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 8410 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.70 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.74 REMARK 3 REFLECTION IN BIN (WORKING SET) : 10178 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.1840 REMARK 3 BIN FREE R VALUE SET COUNT : 550 REMARK 3 BIN FREE R VALUE : 0.2500 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 9148 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 79 REMARK 3 SOLVENT ATOMS : 1045 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 20.79 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.32000 REMARK 3 B22 (A**2) : -1.23000 REMARK 3 B33 (A**2) : 0.92000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.104 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.082 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.050 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.295 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.971 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.959 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9738 ; 0.017 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 8867 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 13282 ; 1.590 ; 1.993 REMARK 3 BOND ANGLES OTHERS (DEGREES): 20708 ; 0.894 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1180 ; 5.701 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 414 ;40.078 ;23.937 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1692 ;13.909 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 48 ;17.764 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1491 ; 0.149 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 10594 ; 0.007 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 1934 ; 0.002 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 2272 ; 0.233 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 9091 ; 0.194 ; 0.200 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 4886 ; 0.180 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): 5208 ; 0.086 ; 0.200 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 860 ; 0.199 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 11 ; 0.356 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): 65 ; 0.345 ; 0.200 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 34 ; 0.364 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 7571 ; 1.674 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9521 ; 1.983 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 4587 ; 2.957 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3761 ; 3.895 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2CCH COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 16-JAN-06. REMARK 100 THE DEPOSITION ID IS D_1290027147. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-NOV-05 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 5.60 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.96865 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 167702 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.700 REMARK 200 RESOLUTION RANGE LOW (A) : 96.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.0 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 15.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.79 REMARK 200 COMPLETENESS FOR SHELL (%) : 91.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.37000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1QMZ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.70 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.90 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 13% PEG MONOMETHYLETHER 5000, 0.2 M REMARK 280 AMMONIUM SULPHATE, 0.1 M CITRATE/ACETATE BUFFER PH 5.6 AT 4 C, REMARK 280 PH 5.60, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.26750 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 90.64950 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.24150 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 90.64950 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.26750 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.24150 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 LEU D 432 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O1 GOL A 1299 O HOH A 2387 1.06 REMARK 500 SG CYS B 193 O HOH B 2130 1.71 REMARK 500 O HOH A 2213 O HOH A 2215 1.79 REMARK 500 SG CYS A 177 O HOH A 2210 1.89 REMARK 500 O HOH A 2337 O HOH A 2341 1.91 REMARK 500 O HOH C 2035 O HOH C 2038 1.94 REMARK 500 O HOH B 2090 O HOH B 2134 1.94 REMARK 500 O3 SO4 A 1298 O HOH A 2386 1.98 REMARK 500 O HOH C 2035 O HOH C 2073 2.03 REMARK 500 O HOH A 2219 O HOH A 2222 2.03 REMARK 500 O HOH C 2005 O HOH C 2014 2.04 REMARK 500 O HOH C 2034 O HOH C 2035 2.04 REMARK 500 O HOH B 2011 O HOH B 2293 2.08 REMARK 500 O HOH A 2079 O HOH A 2213 2.14 REMARK 500 OE2 GLU C 51 O HOH C 2052 2.15 REMARK 500 O1G ATP A 1297 O HOH A 2380 2.16 REMARK 500 O HOH A 2071 O HOH A 2217 2.17 REMARK 500 N SER C 0 O HOH C 2003 2.18 REMARK 500 O HOH B 2296 O HOH B 2314 2.19 REMARK 500 N VAL D 197 O HOH D 2021 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 2235 O HOH A 2386 4555 1.99 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 ARG A 245 CZ ARG A 245 NH1 0.099 REMARK 500 THR B 316 CB THR B 316 CG2 -0.211 REMARK 500 GLU C 51 CD GLU C 51 OE2 -0.081 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 22 NE - CZ - NH1 ANGL. DEV. = 3.9 DEGREES REMARK 500 ARG A 22 NE - CZ - NH2 ANGL. DEV. = -3.3 DEGREES REMARK 500 ARG A 199 CG - CD - NE ANGL. DEV. = -14.0 DEGREES REMARK 500 ARG A 199 CD - NE - CZ ANGL. DEV. = 8.7 DEGREES REMARK 500 ARG A 199 NE - CZ - NH1 ANGL. DEV. = 8.1 DEGREES REMARK 500 ARG A 199 NE - CZ - NH2 ANGL. DEV. = -10.6 DEGREES REMARK 500 ARG A 245 NE - CZ - NH2 ANGL. DEV. = -4.2 DEGREES REMARK 500 ARG A 260 NE - CZ - NH1 ANGL. DEV. = 7.7 DEGREES REMARK 500 ARG A 260 NE - CZ - NH2 ANGL. DEV. = -10.1 DEGREES REMARK 500 ARG B 241 NE - CZ - NH2 ANGL. DEV. = -4.0 DEGREES REMARK 500 MET B 334 CG - SD - CE ANGL. DEV. = 10.2 DEGREES REMARK 500 LEU B 364 CB - CG - CD1 ANGL. DEV. = 11.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 73 -100.48 81.95 REMARK 500 ASP A 127 44.40 -153.04 REMARK 500 ASP A 145 62.78 65.58 REMARK 500 ASP A 145 75.93 48.57 REMARK 500 VAL A 164 132.94 69.68 REMARK 500 SER A 181 -145.44 -151.36 REMARK 500 PHE B 304 18.38 57.24 REMARK 500 TRP B 372 115.59 -35.97 REMARK 500 GLU C 12 134.32 -171.87 REMARK 500 GLU C 73 -109.46 66.14 REMARK 500 ASP C 127 44.93 -154.26 REMARK 500 ASP C 145 78.61 51.07 REMARK 500 ASP C 145 73.99 55.75 REMARK 500 VAL C 164 128.23 76.27 REMARK 500 SER C 181 -147.92 -159.62 REMARK 500 PHE D 304 16.45 57.64 REMARK 500 TRP D 372 108.55 -32.69 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 HIS C 71 THR C 72 -148.74 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2012 DISTANCE = 7.70 ANGSTROMS REMARK 525 HOH B2001 DISTANCE = 6.69 ANGSTROMS REMARK 525 HOH B2002 DISTANCE = 6.39 ANGSTROMS REMARK 525 HOH D2001 DISTANCE = 6.38 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A1298 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ATP A1297 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ATP C1297 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A1299 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A1300 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKU RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P- REMARK 900 F-PHE)-NH2 REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 999 REMARK 999 SEQUENCE REMARK 999 CHAINS B AND D ARE A TRUNCATED FRAGMENT OF CYCLIN A2 REMARK 999 CONSISTING OF RESIDUES 175-432 REMARK 999 CHAINS E AND F ARE PEPTIDES REPRESENTING A FRAGMENT FROM REMARK 999 RESIDUES 89-100 OF CDC6 DBREF 2CCH A 0 0 PDB 2CCH 2CCH 0 0 DBREF 2CCH A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2CCH C 0 0 PDB 2CCH 2CCH 0 0 DBREF 2CCH C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2CCH B 173 432 UNP P20248 CCNA2_HUMAN 173 432 DBREF 2CCH D 173 432 UNP P20248 CCNA2_HUMAN 173 432 DBREF 2CCH E 1 12 UNP Q99741 CDC6_HUMAN 89 100 DBREF 2CCH F 1 12 UNP Q99741 CDC6_HUMAN 89 100 SEQRES 1 A 299 SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 A 299 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 A 299 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 A 299 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 A 299 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 A 299 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 A 299 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 A 299 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 A 299 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 A 299 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 A 299 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 A 299 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 A 299 VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 A 299 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 A 299 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 A 299 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 A 299 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 A 299 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 A 299 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 A 299 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 A 299 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 A 299 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 A 299 PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 B 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 B 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 B 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 B 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 B 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 B 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 B 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 B 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 B 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 B 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 B 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 B 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 B 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 B 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 B 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 B 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 B 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 B 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 B 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 299 SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 C 299 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 C 299 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 C 299 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 C 299 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 C 299 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 C 299 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 C 299 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 C 299 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 C 299 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 C 299 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 C 299 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 C 299 VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 C 299 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 C 299 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 C 299 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 C 299 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 C 299 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 C 299 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 C 299 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 C 299 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 C 299 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 C 299 PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 D 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 D 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 D 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 D 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 D 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 D 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 D 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 D 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 D 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 D 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 D 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 D 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 D 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 D 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 D 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 D 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 D 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 D 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 D 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 E 12 HIS THR LEU LYS GLY ARG ARG LEU VAL PHE ASP ASN SEQRES 1 F 12 HIS THR LEU LYS GLY ARG ARG LEU VAL PHE ASP ASN MODRES 2CCH TPO A 160 THR PHOSPHOTHREONINE MODRES 2CCH TPO C 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HET TPO C 160 11 HET ATP A1297 62 HET SO4 A1298 5 HET GOL A1299 6 HET GOL A1300 6 HET ATP C1297 62 HETNAM TPO PHOSPHOTHREONINE HETNAM ATP ADENOSINE-5'-TRIPHOSPHATE HETNAM SO4 SULFATE ION HETNAM GOL GLYCEROL HETSYN TPO PHOSPHONOTHREONINE HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 7 ATP 2(C10 H16 N5 O13 P3) FORMUL 8 SO4 O4 S 2- FORMUL 9 GOL 2(C3 H8 O3) FORMUL 12 HOH *1045(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 ASP A 145 ALA A 149 5 5 HELIX 6 6 THR A 165 ARG A 169 5 5 HELIX 7 7 ALA A 170 LEU A 175 1 6 HELIX 8 8 THR A 182 ARG A 199 1 18 HELIX 9 9 SER A 207 GLY A 220 1 14 HELIX 10 10 GLY A 229 MET A 233 5 5 HELIX 11 11 ASP A 247 VAL A 251 5 5 HELIX 12 12 ASP A 256 LEU A 267 1 12 HELIX 13 13 SER A 276 LEU A 281 1 6 HELIX 14 14 ALA A 282 GLN A 287 5 6 HELIX 15 15 TYR B 178 CYS B 193 1 16 HELIX 16 16 GLY B 198 GLN B 203 5 6 HELIX 17 17 THR B 207 TYR B 225 1 19 HELIX 18 18 GLN B 228 MET B 246 1 19 HELIX 19 19 LEU B 249 GLU B 269 1 21 HELIX 20 20 GLU B 274 THR B 282 1 9 HELIX 21 21 THR B 287 LEU B 302 1 16 HELIX 22 22 THR B 310 LEU B 320 1 11 HELIX 23 23 ASN B 326 ASP B 343 1 18 HELIX 24 24 ASP B 343 LEU B 348 1 6 HELIX 25 25 LEU B 351 GLY B 369 1 19 HELIX 26 26 PRO B 373 GLY B 381 1 9 HELIX 27 27 THR B 383 ALA B 401 1 19 HELIX 28 28 PRO B 402 HIS B 404 5 3 HELIX 29 29 GLN B 407 LYS B 414 1 8 HELIX 30 30 ASN B 415 HIS B 419 5 5 HELIX 31 31 GLY B 420 LEU B 424 5 5 HELIX 32 32 PRO C 45 LYS C 56 1 12 HELIX 33 33 LEU C 87 SER C 94 1 8 HELIX 34 34 PRO C 100 HIS C 121 1 22 HELIX 35 35 LYS C 129 GLN C 131 5 3 HELIX 36 36 THR C 165 ARG C 169 5 5 HELIX 37 37 ALA C 170 LEU C 175 1 6 HELIX 38 38 THR C 182 ARG C 199 1 18 HELIX 39 39 SER C 207 GLY C 220 1 14 HELIX 40 40 GLY C 229 MET C 233 5 5 HELIX 41 41 ASP C 247 VAL C 252 1 6 HELIX 42 42 ASP C 256 LEU C 267 1 12 HELIX 43 43 SER C 276 ALA C 282 1 7 HELIX 44 44 HIS C 283 GLN C 287 5 5 HELIX 45 45 TYR D 178 CYS D 193 1 16 HELIX 46 46 GLY D 198 GLN D 203 5 6 HELIX 47 47 THR D 207 TYR D 225 1 19 HELIX 48 48 GLN D 228 MET D 246 1 19 HELIX 49 49 LEU D 249 GLU D 269 1 21 HELIX 50 50 GLU D 274 ILE D 281 1 8 HELIX 51 51 THR D 287 LEU D 302 1 16 HELIX 52 52 THR D 310 PHE D 319 1 10 HELIX 53 53 LEU D 320 GLN D 322 5 3 HELIX 54 54 ASN D 326 ASP D 343 1 18 HELIX 55 55 ASP D 343 LEU D 348 1 6 HELIX 56 56 LEU D 351 THR D 368 1 18 HELIX 57 57 PRO D 373 GLY D 381 1 9 HELIX 58 58 THR D 383 ALA D 401 1 19 HELIX 59 59 PRO D 402 HIS D 404 5 3 HELIX 60 60 GLN D 407 TYR D 413 1 7 HELIX 61 61 LYS D 414 HIS D 419 5 6 HELIX 62 62 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 13 0 SHEET 2 AA 5 GLY A 16 ASN A 23 -1 O GLY A 16 N GLY A 13 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 THR A 72 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 13 0 SHEET 2 CA 5 GLY C 16 ASN C 23 -1 O GLY C 16 N GLY C 13 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 THR C 72 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK OD1BASP A 145 O3GBATP A1297 1555 1555 1.17 LINK C TYR A 159 N TPO A 160 1555 1555 1.32 LINK C TPO A 160 N HIS A 161 1555 1555 1.33 LINK C TYR C 159 N TPO C 160 1555 1555 1.34 LINK C TPO C 160 N HIS C 161 1555 1555 1.33 CISPEP 1 VAL A 154 PRO A 155 0 -6.45 CISPEP 2 GLN B 323 PRO B 324 0 -6.73 CISPEP 3 ASP B 345 PRO B 346 0 13.20 CISPEP 4 VAL C 154 PRO C 155 0 -7.33 CISPEP 5 GLN D 323 PRO D 324 0 -7.98 CISPEP 6 ASP D 345 PRO D 346 0 9.71 CISPEP 7 ASP F 11 ASN F 12 0 15.29 SITE 1 AC1 8 ARG A 214 ARG A 217 LYS A 278 HOH A2383 SITE 2 AC1 8 HOH A2384 HOH A2385 HOH A2386 HOH B2070 SITE 1 AC2 28 ILE A 10 GLY A 11 GLU A 12 TYR A 15 SITE 2 AC2 28 VAL A 18 ALA A 31 LYS A 33 GLU A 81 SITE 3 AC2 28 PHE A 82 LEU A 83 ASP A 86 LYS A 89 SITE 4 AC2 28 LYS A 129 GLN A 131 ASN A 132 LEU A 134 SITE 5 AC2 28 ASP A 145 GLY A 147 LEU A 148 HOH A2037 SITE 6 AC2 28 HOH A2374 HOH A2375 HOH A2376 HOH A2377 SITE 7 AC2 28 HOH A2378 HOH A2379 HOH A2380 HOH A2381 SITE 1 AC3 23 ILE C 10 GLY C 11 GLU C 12 TYR C 15 SITE 2 AC3 23 ALA C 31 LYS C 33 GLU C 81 PHE C 82 SITE 3 AC3 23 LEU C 83 ASP C 86 LYS C 89 LYS C 129 SITE 4 AC3 23 GLN C 131 ASN C 132 LEU C 134 ASP C 145 SITE 5 AC3 23 GLY C 147 LEU C 148 HOH C2089 HOH C2141 SITE 6 AC3 23 HOH C2142 HOH C2143 HOH C2144 SITE 1 AC4 9 PHE A 109 ILE A 209 PHE A 213 LYS A 237 SITE 2 AC4 9 SER A 239 PHE A 286 GLN A 287 HOH A2387 SITE 3 AC4 9 HOH A2388 SITE 1 AC5 9 HIS A 60 GLN A 113 ALA A 116 PHE A 117 SITE 2 AC5 9 LYS A 242 TRP A 243 HOH A2285 HOH A2389 SITE 3 AC5 9 HOH A2390 CRYST1 74.535 114.483 181.299 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013417 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008735 0.000000 0.00000 SCALE3 0.000000 0.000000 0.005516 0.00000